Healthcare -
Biotechnology - NASDAQ - US
$ 0.4261
0.223 %
$ 10 M
Market Cap
-0.64
P/E
1. INTRINSIC VALUE
Balance Sheet
Acurx Pharmaceuticals, Inc.
| Current Assets | 3.86 M |
| Cash & Short-Term Investments | 3.71 M |
| Receivables | 51.1 K |
| Other Current Assets | 99.9 K |
| Non-Current Assets | 0 |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 0 |
| Current Liabilities | 3.24 M |
| Accounts Payable | 0 |
| Short-Term Debt | 0 |
| Other Current Liabilities | 3.24 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Acurx Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 14.1 M |
| Operating Income | -14.1 M |
| Other Expenses | 0 |
| Net Income | -14.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Acurx Pharmaceuticals, Inc.
| Net Income | -14.1 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 3.44 M |
| Change in Working Capital | 284 K |
| Others | 3.64 M |
| Free Cash Flow | -10.4 M |
Wall Street Analysts Price Targets
Acurx Pharmaceuticals, Inc.
ACXP has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ACXP does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Acurx Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
321 K USD 6
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
STATEN ISLAND, N.Y. , June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per share, resulting in gross proceeds of approximately $2.67 million, before deducting offering fees and other expenses payable by the Company.
prnewswire.com
- 1 month ago
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) recurrence through one month after EOT In contrast, 2 of 14 (14%) patients treated with the standard of care, oral vancomycin, experienced recurrent infection within one month after EOT When Phase 2b results are combined with Phase 2a results, 25 of 25 (100%) ibezapolstat-treated patients with CDI who had CC at EOT remained recurrence-free through 1 month after EOT; additionally, all 5 Phase 2b ibezapolstat-treated patients observed for up to 3 months following CC experienced no recurrence of infection Adding to this Lancet Microbe publication, two recent Journal of Antimicrobial Agents and Chemotherapeutics publications regarding, respectively, favorable gut microbiome effects which differentiate IBZ from other anti-CDI antibiotics and positive results from an in-silico study predicting the microbiome-restorative potential of IBZ The totality of ibezapolstat data-to-date further advances Acurx's robust data package and are reshaping the therapeutic landscape for future treatment of CDI with ibezapolstat's innovative and potentially transformative new class of antibiotics to treat gram-positive infections while preserving and restoring the protective gut microbiota Acurx is well positioned to begin international Phase 3 clinical trials and has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.
prnewswire.com
- 1 month ago
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials for C. difficile Infection (CDI), with no cross resistance reported to date Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y.
prnewswire.com
- 1 month ago
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and CFO David Luci - President and CEO Conference Call Participants Joanne Lee - Maxim Group James Molloy - Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 Financial Results and Business Update. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 2 months ago
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
STATEN ISLAND, N.Y. , May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.
prnewswire.com
- 2 months ago
Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
STATEN ISLAND, N.Y. , April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open.
prnewswire.com
- 3 months ago
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
STATEN ISLAND, N.Y. , April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P.
prnewswire.com
- 3 months ago
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025.
prnewswire.com
- 3 months ago
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
zacks.com
- 3 months ago
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 4 months ago
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Thomas Yip - H.C. Wainwright James Molloy - Alliance Global Partners Claire Acheson - Independent Investment Research Operator Greetings and welcome to the Acurx Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results and Business Update.
seekingalpha.com
- 4 months ago
8. Profile
Summary
Acurx Pharmaceuticals, Inc. ACXP
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 10 M
Dividend Yield
0.00%
Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Contact
259 Liberty Avenue, Staten Island, NY, 10305
https://www.acurxpharma.com
IPO
Date
June 25, 2021
Employees
4
Officers
Mr. Robert G. Shawah CPA
Co-Founder & Chief Financial Officer
Mr. David P. Luci CPA, Esq., J.D.
Co-Founder, President, Chief Executive Officer, Corporate Secretary & Director
Mr. Robert J. DeLuccia
Co-Founder & Executive Chairman